Okklo Life Sciences
  • Company
    • Mission & Vision
    • Management Team
    • Advisors
    • Investors
  • Technology
    • Cyclodextrins
    • Therapeutic CDs
    • OKKLO’s CD Technology
  • Programs
    • Hemostasis
    • Cystic Fibrosis
    • Immunology
    • Lysosomal Storage Disease (NPC)
  • Partnering
  • News
  • Contact
    • Where to meet us
    • Disclaimer
Home » Programs

Programs

Okklo is currently working in a variety of therapeutic areas:

  • Hemostasis (hemophilia and anticoagulant reversal)
  • Cystic fibrosis
  • Immunology (undisclosed target)
  • Lysosomal storage diseases (Niemann-Pick type C disease).

Programs

  • Hemostasis
  • Cystic Fibrosis
  • Immunology
  • Lysosomal Storage Diseases (NPC)
  • Pipeline

RSS Drug Discovery Today

  • EIT Health Catapult 2022 names health start-up winners 05/26/2022
  • New £20m Life Sciences Fund Launches to Support SMEs In Greater Manchester, Cheshire and Warrington 05/26/2022
  • Evonetix Granted Patent for Binary Assembly Method for Gene Synthesis 05/10/2022
  • Thirona’s RetCAD™ and iCare are joining forces in Europe to offer an integral solution for eye screening with artificial intelligence. 04/29/2022
  • Proofig launches first commercial automated image duplication and manipulation detection software for scientific publications 04/19/2022

Follow us on:

Contact us LinkedIn

Recent Okklo News

  • Okklo’s hematology asset will be further developed by Alveron Pharma 05/16/2019
  • Okklo and SolAeroMed partner to develop cyclodextrins for cystic fibrosis treatment 06/27/2017
  • Okklo Life Sciences B.V. and Sanquin sign commercialization agreement to enter IND enabling studies and clinical development. 01/10/2017
  • Okklo receives RedMedTech Ventures funding and extends collaboration with Sanquin 05/15/2016
  • Company
  • Technology
  • Programs
  • Partnering
  • News
  • Contact
Copyright © 2016 | Okklo Life Sciences | All Rights Reserved